AI innovator disrupting the pharmaceutical industry joins the ranks of Microsoft, Apple, Novartis, and more
With a platform that can predict which drug candidates will work in humans—and eliminate the costly and inefficient practice of testing on animals—Quris hopes to revolutionize drug development.
Quris expands Seed funding to $37 million with latest $9 million investment led by SoftBank Vision Fund 2, alongside existing private and institutional investors, strengthening momentum to close drug development gaps.
Six startup companies have been selected to participate in the BeyondBio SCALE program led by pharmaceutical giant AstraZeneca, Accenture, Amazon Web Services and Clalit - the largest healthcare organization in Israel.
Merck KGaA, Darmstadt, Germany, Enters into Option Agreement with Quris on its BioAI Platform for Clinical Safety Prediction. The agreement between the two companies is exclusive to only one disease for a period of five years.
Quris Launches First AI Clinical Prediction Platform
A disruptive bio-AI platform that combines cutting-edge machine-learning, together with miniaturized Patients-on-a-Chip to predict drug safety and efficacy.
Moderna Co-founder Robert Langer Joins Quris’ SAB
“We are at the tipping point of modernization of drug discovery. I think the Quris platform could be of significant value to pharma companies" – Prof. Robert Langer
Nobel Laureate Ciechanover Chairs Quris’ Scientific Advisory Board
“Quris can evaluate the safety and efficacy of drug candidates using a breakthrough method on miniaturized Patients-on-a-Chip." – Nobel Laureate Ciechanover